U.S. biotech insider trading diverges: ImmunityBio (IBRX.US) cashes out the most, while a Sellas (SLS.US) director bought before a 5-fold surge

date
16:26 12/11/2026
avatar
GMT Eight
Insider trading at U.S. biotech companies is diverging.
In the biotech sector, drug development progress is certainly the core variable for stock prices, but insider buying and selling activity is also an important factor in assessing a company's prospects. From this perspective, the insider moves at four companiesCapricor (CAPR.US), ImmunityBio (IBRX.US), Sellas (SLS.US), and Iovance (IOVA.US)present starkly different pictures: some cashed out at highs, some bought against the trend, and others stayed put. According to data compiled by Fiscal AI, over the past year, insiders at Capricor and ImmunityBio collectively cashed out nearly US$18 million through share sales; Sellas director Katherine Bach Kalin was the only insider among the four companies to buy in the open market, and the stock surged after her purchase, yielding an unrealized gain of about 430%; by contrast, Iovance insiders conducted no open-market transactions during the same period. ImmunityBio: Three directors collectively cashed out US$9.51 million ImmunityBio director Barry Simon cashed out US$4.41 million through share sales over the past year, the most among insiders at the four companies. He, along with directors Cheryl Cohen and Christobel Selecky, collectively sold 1.04 million shares, cashing out US$9.51 million. Simon's last transaction was the sale of 25,000 shares on October 5, reducing his direct holdings by less than 1%, and he still held nearly 2.78 million shares after the trade. Cohen's October 2 transaction had a greater impact on her holdings: she exercised 55,979 options at US$2.98 and sold 81,056 shares at US$10.50, for a net reduction of 25,077 shares that day. Her October transactions together with Simon's cashed out US$1.12 million. All three directors sold shares under pre-arranged Rule 10b5-1 trading plans. The October transactions occurred shortly before the FDA on October 14 expanded Anktiva's bladder cancer indication. ImmunityBio CEO Richard Adcock said: "This label expansion is a significant opportunity to bring ANKTIVA to a broader patient population." Capricor: Three executives sold after exercising options, cashing out US$8.37 million Capricor CFO Anthony Bergmann, General Counsel Karen Krasney, and director Karimah Es Sabar sold 272,529 shares between March 31 and June 25, cashing out US$8.37 million. All 13 transactions were matched with options exercised on the same day, thereby preserving their previously held common shares. After paying approximately US$1.07 million in exercise costs, the three collectively received US$7.30 million, before taxes and fees. The three established trading plans in December 2025, months before the FDA restarted its review of Deramiocel in March. They completed their sales before the FDA's unfavorable advisory vote in July on the therapy for treating heart disease associated with Duchenne muscular dystrophy. Capricor is now awaiting an FDA decision on November 22 on its amended application, which focuses on upper limb and hand function impairment in Duchenne muscular dystrophy patients aged 9 and older. CEO Linda Marban said: "As the PDUFA date approaches, we remain confident in our data." Sellas: Insider's unrealized gain of 430% after purchase Sellas director Katherine Bach Kalin purchased 63,400 shares on November 19, 2025, worth approximately US$100,806. A week earlier, the company had just updated investors on the latest progress of its Regal leukemia trial. The purchase more than doubled her direct holdings to 104,400 shares. If she has held to date, based on Wednesday's stock price, the investment would be worth US$534,000, equivalent to 5.3 times the purchase cost, with an unrealized gain of approximately US$433,000, or 430%. The Regal Phase 3 trial last month reached the 80 death events required for the final survival analysis. The trial is designed to test whether Galinpepimut-S can help acute myeloid leukemia (AML) patients extend survival after a second complete remission, with results expected this quarter. CEO Angelos Stergiou said: "Reaching the 80th event is a key milestone for the Regal trial." Institutional investors have also increased their exposure to Sellas. According to Fiscal AI data, in the quarter ended June 30, institutions net-added 18.8 million shares, raising their ownership to 36%. During the same period, institutions reduced their holdings in Capricor by 1.9 million shares but still held 55% of the company. Iovance: Insiders stay put, Amtagvi sales continue to climb Unlike the other three companies, Iovance insiders conducted no open-market transactions over the past year, and sales of its melanoma cell therapy Amtagvi continued to grow. Amtagvi U.S. sales grew 77% to approximately US$102 million, driving third-quarter product revenue up 80% year over year. Interim CEO Frederick Vogt said: "Third-quarter revenue reached a new record of approximately US$122 million, with the highest gross margin in history, driven by continued U.S. demand for Amtagvi." The company maintained its 2026 revenue forecast of US$410 million to US$420 million and plans to submit an application to the FDA in 2027 to expand Amtagvi's indication to lung cancer. Retail investors bullish on Capricor, ImmunityBio; bearish on Sellas and Iovance On the Stocktwits platform, retail sentiment on Capricor was "extremely bullish" with "extremely high" message volume, ranking first among the four companies; ImmunityBio sentiment was "bullish" with "high" message volume; Sellas and Iovance each showed "bearish" sentiment, with message volume "normal" and "low," respectively. One user commented on Capricor: "I'm bullish on approval but still see significant risk." Another user said: "Regular communication cadence, such as quarterly updates or periodic shareholder letters, would go a long way toward building confidence." Yet another user said: "If REGAL delivers good results, this could be the company's defining moment." In terms of year-to-date gains, ImmunityBio led with a 237% increase, Iovance rose 196%, Sellas rose 123%, while Capricor fell 61%, underperforming.